Pharvaris Bv Stock Today
| PHVS Stock | USD 22.36 1.81 7.49% |
Performance9 of 100
| Odds Of DistressLess than 45
|
Pharvaris is selling for under 22.36 as of the 28th of November 2024; that is 7.49 percent down since the beginning of the trading day. The stock's lowest day price was 21.33. Pharvaris has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Pharvaris BV are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of February 2021 | Category Healthcare | Classification Health Care |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company was incorporated in 2015 and is based in Leiden, the Netherlands. Pharvaris is traded on NASDAQ Exchange in the United States. The company has 54.23 M outstanding shares of which 137.27 K shares are at this time shorted by private and institutional investors with about 1.49 trading days to cover. More on Pharvaris BV
Moving against Pharvaris Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pharvaris Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPharvaris can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pharvaris' financial leverage. It provides some insight into what part of Pharvaris' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Pharvaris BV (PHVS) is traded on NASDAQ Exchange in USA. It is located in Emmy Noetherweg 2, Leiden, Netherlands, 2333 BK and employs 83 people. Pharvaris is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.31 B. Pharvaris BV conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.23 M outstanding shares of which 137.27 K shares are at this time shorted by private and institutional investors with about 1.49 trading days to cover.
Pharvaris BV currently holds about 201.38 M in cash with (93.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.96.
Check Pharvaris Probability Of Bankruptcy
Ownership AllocationPharvaris owns a total of 54.23 Million outstanding shares. The majority of Pharvaris BV outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pharvaris BV to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pharvaris. Please pay attention to any change in the institutional holdings of Pharvaris BV as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Pharvaris Ownership Details
Pharvaris Historical Income Statement
Pharvaris Stock Against Markets
Pharvaris Corporate Management
| Peng MD | Chief Officer | Profile | |
| Morgan Conn | Chief Officer | Profile | |
| Jochen Knolle | Chief COO | Profile | |
| CPA MBA | CEO CoFounder | Profile | |
| Joan JD | Chief Officer | Profile | |
| Stefan Abele | Chief Officer | Profile | |
| Wim Souverijns | Chief Officer | Profile |
Additional Tools for Pharvaris Stock Analysis
When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.